NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions

Front Immunol. 2023 Jan 19:13:1087689. doi: 10.3389/fimmu.2022.1087689. eCollection 2022.

Abstract

Exosomes are membranous vesicles actively secreted by almost all cells and they deliver certain intracellular molecules, including nucleic acids, proteins, and lipids, to target cells. They are also considered to be good carriers for drug delivery due to their biocompatibility, high permeability, low immunogenicity, and low toxicity. Exosomes from immune cells were also reported to have immunomodulatory activities. Herein we evaluated the application of exosomes derived from expanded natural killer cells (eNK-EXO) for the treatment of ovarian cancer (OC). We demonstrate that eNK-EXO express typical protein markers of natural killer (NK) cells, can be preferentially uptaken by SKOV3 cells, and display cytotoxicity against OC cells. Furthermore, eNK-EXO loaded with cisplatin could sensitize drug-resistant OC cells to the anti-proliferation effect of cisplatin. In addition, we show that eNK-EXO could activate NK cells from immunosuppressive tumor microenvironment, the mechanism of which is explored by transcriptional analysis. In summary, eNK-EXO exhibit anti-tumor activity against OC on its own, could be used to deliver cisplatin and enhance its cytotoxic effect against drug-resistant OC cells and also reverse the immunosuppression of NK cells, which may lead to great prospect of using eNK-EXO in the treatment of OC in the clinic. Our work also builds a strong foundation for further evaluation of eNK-EXO in other solid tumor therapies.

Keywords: cisplatin; exosomes; immunomodulatory; natural killer cells; ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Exosomes* / metabolism
  • Female
  • Humans
  • Killer Cells, Natural
  • Ovarian Neoplasms* / metabolism
  • Tumor Microenvironment

Substances

  • Cisplatin
  • Antineoplastic Agents

Grants and funding

This work was supported by the Science and Technology Program of Guizhou Province (grant number: [2019]1263) and Key Program for Science and Technology of Guizhou Province [grant number:ZK(2021)012] provided to XZ. Funded by the National Natural Science Foundation of China, (grant number:12132006) and Guizhou Provincial Natural Science Foundation (grant number: 2018-1412 and 2016-5676) provided to ZZ. Funded by the National Natural Science Foundation of China (grant No.81860460) and the Science and Technology Fund of Guizhou Province (grant NO.ZK[2022]270) provided to DZ.